Vicore Pharma Holding AB
STO:VICO

Watchlist Manager
Vicore Pharma Holding AB Logo
Vicore Pharma Holding AB
STO:VICO
Watchlist
Price: 7.91 SEK 1.67% Market Closed
Market Cap: 1.9B SEK
Have any thoughts about
Vicore Pharma Holding AB?
Write Note

Vicore Pharma Holding AB
Research & Development

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Vicore Pharma Holding AB
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
Vicore Pharma Holding AB
STO:VICO
Research & Development
-kr275m
CAGR 3-Years
-26%
CAGR 5-Years
-65%
CAGR 10-Years
N/A
Biogaia AB
STO:BIOG B
Research & Development
-kr104.4m
CAGR 3-Years
0%
CAGR 5-Years
-1%
CAGR 10-Years
N/A
Bonesupport Holding AB
STO:BONEX
Research & Development
-kr71.7m
CAGR 3-Years
-23%
CAGR 5-Years
-1%
CAGR 10-Years
N/A
Vitrolife AB
STO:VITR
Research & Development
-kr115m
CAGR 3-Years
-13%
CAGR 5-Years
-6%
CAGR 10-Years
-8%
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Research & Development
-kr3.3B
CAGR 3-Years
-32%
CAGR 5-Years
-18%
CAGR 10-Years
-22%
BioArctic AB
STO:BIOA B
Research & Development
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Vicore Pharma Holding AB
Glance View

Market Cap
1.9B SEK
Industry
Biotechnology

Vicore Pharma Holding AB is a pharmaceutical company, which engages in the development of drugs with focus on interstitial lung diseases and related indications. The company is headquartered in Goeteborg, Vastra Gotalands. The company went IPO on 2015-12-10. The firm's portfolio contains small molecules with potential indications, including anti-inflammation, nerve generation and cardiovascular disease. The firm is a wholly owned subsidiary of Mintage Scientific AB.

VICO Intrinsic Value
2.94 SEK
Overvaluation 63%
Intrinsic Value
Price

See Also

What is Vicore Pharma Holding AB's Research & Development?
Research & Development
-275m SEK

Based on the financial report for Jun 30, 2024, Vicore Pharma Holding AB's Research & Development amounts to -275m SEK.

What is Vicore Pharma Holding AB's Research & Development growth rate?
Research & Development CAGR 5Y
-65%

Over the last year, the Research & Development growth was -20%. The average annual Research & Development growth rates for Vicore Pharma Holding AB have been -26% over the past three years , -65% over the past five years .

Back to Top